Who is sponsoring NCT03859986?

NCT03859986 is sponsored by Ralexar Therapeutics, Inc..

What condition does NCT03859986 study?

NCT03859986 studies Atopic Dermatitis Eczema.

What drugs are being tested in NCT03859986?

Interventions: ALX-101 Gel Vehicle, ALX-101 Gel 5%.

What is the status of NCT03859986?

NCT03859986 is currently UNKNOWN.

Last reviewed 2019-11-04 · How we verify

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of ALX-101 Topical Gel Administered Twice Daily In Adult And Adolescent Subjects With Moderate Atopic Dermatitis

NCT03859986 Phase 2 UNKNOWN

This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in adult and adolescent subjects with moderate atopic dermatitis

Details

Lead sponsor	Ralexar Therapeutics, Inc.
Phase	Phase 2
Status	UNKNOWN
Enrolment	124
Start date	2019-03-08
Completion	2020-01

Conditions

Atopic Dermatitis Eczema

Interventions

ALX-101 Gel Vehicle
ALX-101 Gel 5%

Primary outcomes

Eczema Area Severity Index (EASI) — Day 57
Mean change from baseline in EASI score at Week 8

Countries

United States, Canada